These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30356163)

  • 1. Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease.
    Danylesko I; Bukauskas A; Paulson M; Peceliunas V; Gedde-Dahl D Y T; Shimoni A; Shouval R; Griskevicius L; Floisand Y; Nagler A
    Bone Marrow Transplant; 2019 Jul; 54(7):987-993. PubMed ID: 30356163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.
    Gao Z; Fan Z; Liu Z; Ye X; Zeng Y; Xuan L; Huang F; Lin R; Sun J; Liu Q; Xu N
    Front Immunol; 2024; 15():1408211. PubMed ID: 39021571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vedolizumab in highly resistant acute gastrointestinal graft-versus-host disease after allogeneic stem cell transplantation: A single-center pediatric series.
    Rosa M; Jarmoliński T; Miśkiewicz-Migoń I; Liszka K; Miśkiewicz-Bujna J; Panasiuk A; Frączkiewicz J; Ussowicz M
    Adv Clin Exp Med; 2022 Mar; 31(3):345-350. PubMed ID: 35212198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review.
    Fløisand Y; Lazarevic VL; Maertens J; Mattsson J; Shah NN; Zachée P; Taylor A; Akbari M; Quadri S; Parfionovas A; Chen YB
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):720-727. PubMed ID: 30468919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.
    Chen YB; Mohty M; Zeiser R; Teshima T; Jamy O; Maertens J; Purtill D; Chen J; Cao H; Rossiter G; Jansson J; Fløisand Y
    Nat Med; 2024 Aug; 30(8):2277-2287. PubMed ID: 38844797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease.
    Fløisand Y; Lundin KEA; Lazarevic V; Kristiansen JD; Osnes LTN; Tjønnfjord GE; Reims HM; Gedde-Dahl T
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):172-175. PubMed ID: 27777142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vedolizumab for pediatric patients with gastrointestinal acute graft-versus-host-disease.
    Aldouby Bier G; Zaidman I; Dinur Schejter Y; NaserEddin A; Stepensky P; Even-Or E
    Pediatr Blood Cancer; 2023 Jan; 70(1):e30061. PubMed ID: 36326084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
    Yucebay F; Matthews C; Puto M; Li J; William B; Jaglowski SM; Penza SL; Vasu S; Benson DM; Andritsos LA; Devine SM; Efebera YA; Roddy JVF
    Leuk Lymphoma; 2019 Sep; 60(9):2223-2229. PubMed ID: 30764681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.
    van Groningen LF; Liefferink AM; de Haan AF; Schaap NP; Donnelly JP; Blijlevens NM; van der Velden WJ
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):179-82. PubMed ID: 26386320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review.
    Fukuta T; Muramatsu H; Yamashita D; Sajiki D; Maemura R; Tsumura Y; Yamamori A; Imaya M; Wakamatsu M; Nishikawa E; Narita K; Kataoka S; Taniguchi R; Narita A; Nishio N; Takahashi Y
    Int J Hematol; 2023 Sep; 118(3):411-417. PubMed ID: 37074509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α4β7 Integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease.
    Ibrahimova A; Davies SM; Lane A; Jordan MB; Lake K; Litts B; Chaturvedi V; Owsley E; Myers KC; Nelson AS; Mehta PA; Marsh RA; Khandelwal P
    Pediatr Blood Cancer; 2021 Aug; 68(8):e28968. PubMed ID: 33861521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vedolizumab for second-line treatment of steroid-refractory gastrointestinal late acute graft-versus-host disease.
    Zu Y; Gui R; Li Z; Wang J; Li P; Liu Y; Dong X; Zhou J
    Ther Adv Hematol; 2024; 15():20406207241276982. PubMed ID: 39247427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease.
    Mehta RS; Saliba RM; Jan A; Shigle TL; Wang E; Nieto Y; Ciurea SO; Oran B; Im J; Olson A; Marin D; Qazilbash M; Khouri I; Rondon G; Anderlini P; Rezvani K; Popat U; Kebriaei P; Shpall E; Champlin R; Alousi A
    Transplant Cell Ther; 2021 Mar; 27(3):272.e1-272.e5. PubMed ID: 33781539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
    Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease.
    Isshiki K; Kamiya T; Endo A; Okamoto K; Osumi T; Kawai T; Arai K; Tomizawa D; Ohtsuka K; Nagahori M; Imai K; Kato M; Kanegane H
    Int J Hematol; 2022 Apr; 115(4):590-594. PubMed ID: 34724153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vedolizumab for acute gastrointestinal graft-versus-host disease: A systematic review and meta-analysis.
    Li AC; Dong C; Tay ST; Ananthakrishnan A; Ma KS
    Front Immunol; 2022; 13():1025350. PubMed ID: 36439135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease.
    Fløisand Y; Schroeder MA; Chevallier P; Selleslag D; Devine S; Renteria AS; Mohty M; Yakoub-Agha I; Chen C; Parfionovas A; Quadri S; Jansson J; Akbari M; Chen YB
    Bone Marrow Transplant; 2021 Oct; 56(10):2477-2488. PubMed ID: 34108672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverting Enterostomy Improves Overall Survival of Patients With Severe Steroid-refractory Gastrointestinal Acute Graft-Versus-Host Disease.
    Khodr J; Zerbib P; Rogosnitzky M; Magro L; Truant S; Yakoub-Agha I; Duhamel A; Seguy D
    Ann Surg; 2021 Nov; 274(5):773-779. PubMed ID: 34342300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
    Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
    Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.